Building Competency in Diabetes Education THE ESSENTIALS

TREATMENT MODALITIES: PHARMACOLOGICAL THERAPIES | 6-128

64. Novo Nordisk Canada Inc. Ozempic product monograph. Mississauga, Novo Nordisk Canada, 2019. 65. GlaxoSmithKline Inc. Bydureon product monograph. Mississauga: GlaxoSmithKline, 2018. 66. GlaxoSmithKline Inc. Eperzan product monograph. Mississauga: GlaxoSmithKline, 2016. 67. Shah BR, Hux JE, Laupacis A, et al. Clinical inertia in response to inadequate glycemic control: Do specialists differ from primary care physicians. Diabetes Care 2005;28:600-6. 68. Fowler MJ. Diabetes treatment, part 3: Insulin and incretins. Clin Diabetes 2008;26:35-9. 69. Taylor JR, Campbell KM. Diabetes drug update: How 4 new options stack up. J Family Pract 2007:56:207-15. 70. Drucker D. The evidence for achieving glycemic control with incretin mimetics. Diabetes Educ 2006;32(Suppl 2):72S-81S. 71. American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2018. Diabetes Care 2018;41(Suppl 1):S73-S85. 72. Buse JB Rosenstock J, Giorio S, et al; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374:39-47. 73. Buse JB, Sesti G, Schmidt WE, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010;33:1300-3. 74. Thrasher J. Pharmacologic management of type 2 diabetes mellitus: Available therapies. Am J Cardiol 2017;120(Supp 1):S4-S16. 75. Lingvay I, Desouza CV, Lalic KS, et al. A 26-Week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin. Diabetes Care 2018;41(Suppl 9):1926-37. 76. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 2010;27:136-42. 77. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: The pleiotropic effects of SGLT2 inhibition. Diabetologia 2017;60:215-25. 78. Kosiborod M, Cavender MA, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The